About This Research Study
Metabolic Dysfunction-Associated Steatohepatitis (MASH) is a severe, progressive liver disease caused by fat buildup, inflammation, and liver cell damage, often linked to obesity and diabetes. Tekton Research is now enrolling a clinical study evaluating an investigational medication for the possible treatment of MASH. Eligible participants may be compensated for study-related travel and study-related expenses.
Eligible participants…
- Must be age 30 or older
- Must have a BMI between 27-44
- Must have stable bodyweight for the last 3 months
- Must NOT have had any type of bariatric surgery
- Must NOT be taking GLP-1 agonists or other weight loss medication/therapies
- Must have Gallbladder still intact
- Must not be taking insulin for T2D management
- May receive compensation for study-related travel and study-related expenses
- Do not need insurance to join this study
For more information, complete the form on this page. After you submit your information, a Tekton enrollment specialist will call you to talk about the study. There is no obligation to participate — you can decide if the study is right for you.